1-20 of 32
Amit Agarwal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John F. Seymour, Constantine S. Tam, Chan Y. Cheah, Ricardo D. Parrondo, John N. Allan, Judith Trotman, Ranjana H. Advani, Herbert A. Eradat, Pier Luigi Zinzani, Masa Lasica, Steven P. Treon, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Anna Maria Frustaci
Journal: Blood
Blood (2024) 144 (Supplement 1): 860.
https://doi.org/10.1182/blood-2024-199212
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour
Journal: Blood
Blood (2024) 144 (Supplement 1): 885.
https://doi.org/10.1182/blood-2024-199116
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Constantine S. Tam, Anna Maria Frustaci, Fontanet Bijou, Pier Luigi Zinzani, John F. Seymour, Masa Lasica, Herbert A. Eradat, Victor T.G. Lin, Maan Alwan, Irina Mocanu, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Chan Y. Cheah
Journal: Blood
Blood (2024) 144 (Supplement 1): 1649.
https://doi.org/10.1182/blood-2024-199154
Published: 2024
Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Herve Ghesquieres, Krimo Bouabdallah, Marc Andre, Philippe Quittet, Cecile Borel, Aspasia Stamatoulas Bastard, Michael Gilbertson, Fabien Le Bras, Catherine Thieblemont, Baptiste Delapierre, Mohamed Touati, Pierre Feugier, Julien Lazarovici, Nadine Morineau, Thomas Gastinne, Isabelle Chaillol, Rod Ramchandren, Harsh Shah, Dipenkumar Modi, Heather Allewelt, Pierre Fustier, Jianfeng Xu, Amit Agarwal, Franck Morschhauser, Cedric Rossi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1717.
https://doi.org/10.1182/blood-2023-188545
Published: 2023
Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal
Journal: Blood
Blood (2023) 142 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2023-178735
Published: 2023
Journal Articles

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Yoon Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael L. Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason Paik, Amit Agarwal, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 4401.
https://doi.org/10.1182/blood-2023-180109
Published: 2023
Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Clinical Trials & Observations
Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta
Journal: Blood
Blood (2023) 141 (13): 1574–1583.
https://doi.org/10.1182/blood.2022016212
Published: 2023
Includes: Supplemental data
Journal Articles

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Nina Shah, Nikhil C. Munshi, Jesús G. Berdeja, Sundar Jagannath, Olivia Finney, Nathan Martin, Amit Agarwal, Everton Rowe, Timothy B. Campbell, Jesús F. San-Miguel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1739.
https://doi.org/10.1182/blood-2021-148375
Published: 2021
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-134319
Published: 2020
Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134189
Published: 2020
Journal Articles

Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Ankit Kansagra, MD, Yi Lin, MD PhD, Jesus G. Berdeja, MD, Nina Shah, MD, Albert Oriol, MD, Ibrahim Yakoub-Agha, Hermann Einsele, MD, Alessandro Rambaldi, MD, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Julie Wang, PharmD, PhD, Amit Agarwal, MD PhD, Timothy B. Campbell, MD PhD, Sagar Lonial, MD FACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-134383
Published: 2020
Journal Articles

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Julie Rytlewski, PhD, Deepu Madduri, MD, Jaymes Fuller, PhD, Timothy B. Campbell, MD PhD, Afshin Mashadi-Hossein, MSc, Ethan G. Thompson, PhD, Yue Jiang, PhD, Nathan Martin, PhD, Dipen Sangurdekar, PhD, Olivia Finney, PhD, Hans Bitter, PhD, Amit Agarwal, MD PhD, Shari Kaiser, PhD, Kristen Hege, MD, Ronald J. Hause, Jr., PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-134369
Published: 2020
Journal Articles

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Noopur S. Raje, MD, Omar Nadeem, MD, Joseph Mikhael, MD FRCPC, MD, Catherine Ludwig, MB BChir, Amit Agarwal, MD PhD, Judith Inumerable, PGC, Teng J. Ong, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-141591
Published: 2020
Journal Articles

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Ethan G. Thompson, PhD, Yue Jiang, PhD, Timothy B. Campbell, MD PhD, Jaymes Fuller, PhD, Shari Kaiser, PhD, Afshin Mashadi-Hossein, MSc, Julie Rytlewski, PhD, Nathan Martin, PhD, Olivia Finney, PhD, Katja Kleinsteuber, PhD, Eric Alonzo, PhD, Chetanya Pandya, PhD, Amit Agarwal, MD PhD, Kristen Hege, Noopur S. Raje, MD, Nikhil C. Munshi, MD, Ronald J. Hause, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4328.
https://doi.org/10.1182/blood-2019-124998
Published: 2019
Journal Articles

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Hans C. Lee, MD, Sikander Ailawadhi, MD, Cristina Gasparetto, MD, Sundar Jagannath, Robert M. Rifkin, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne I. Wagner, PhD, James L. Omel, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Amit Agarwal, MD PhD, Rafat Abonour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3129.
https://doi.org/10.1182/blood-2019-126205
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective

Zheng-Yi Zhou, PhD, Kejal Parikh, Xinglei Chai, Ariel Rokito, Chuka Udeze, Jipan Xie, Amit Agarwal
Journal: Blood
Blood (2018) 132 (Supplement 1): 3535.
https://doi.org/10.1182/blood-2018-99-112942
Published: 2018
Journal Articles

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, MD, Gustavo Fonseca, Donna Reece, Amit Agarwal, MD PhD, Weiyuan Chung, Faiza Zafar, MPAS, Nizar Bahlis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3271.
https://doi.org/10.1182/blood-2018-99-111920
Published: 2018
Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

William E. Pierceall, Nizar Bahlis, MD, David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Shanti Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, Gustavo Fonseca, Donna Reece, Weiyuan Chung, Natalya Serbina, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2012.
https://doi.org/10.1182/blood-2018-99-111554
Published: 2018
Journal Articles

Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis

Ajai Chari, MD, Brian Ung, Marc Tian, Amit Agarwal, MD PhD, Kejal Parikh
Journal: Blood
Blood (2018) 132 (Supplement 1): 2243.
https://doi.org/10.1182/blood-2018-99-111121
Published: 2018
Journal Articles

Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status

Greg E. Pietz, BS, MS, Mark Tometsko, BSc, Wilbert B. Copeland, PhD, Elizabeth Whalen, PhD, Frank Schmitz, MD PhD, Ethan G. Thompson, PhD, Amit Agarwal, MD PhD, Teresa Foy, PhD, Lauren Buchholz, BS, Vitalina Komashko, PhD, Justine Dell'Aringa, BSc, Brian A. Fox, PhD, Kathryn Newhall, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3161.
https://doi.org/10.1182/blood-2018-99-115107
Published: 2018